View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 10, 2019updated 17 Aug 2022 12:28pm

UC Berkeley develops drug sponge to soak up chemotherapy side effects

Chemical engineers at University of California, Berkeley (UC Berkeley) have developed a drug sponge that could absorb the residual chemotherapy drug and minimise cancer treatment side effects.

Chemical engineers at the University of California, Berkeley (UC Berkeley) have developed a drug sponge that could absorb the residual chemotherapy drug and minimise cancer treatment side effects.

To be inserted in the bloodstream, the sponge is also expected to enable the delivery of higher doses to fight cancers in organs such as the liver, which do not respond to more benign therapies.

The team developed the drug sponge by coating a 3D printed cylinder with absorbent polymer. The cylinder is tailored to fit precisely in a vein that carries the blood out of the target organ.

A wire is passed into the bloodstream to insert the drug sponge, which is left in the vein throughout the chemotherapy duration.

This placement is intended to soak up any residual drug not absorbed by the tumour and prevent it from affecting other organs.

UC San Francisco interventional radiologist Steven Hetts said: “We are developing this around liver cancer because it is a big public health threat – there are tens of thousands of new cases every year – and we already treat liver cancer using intra-arterial chemotherapy.

“You could use this sort of approach for any tumour or any disease that is confined to an organ, and you want to absorb the drug on the venous side before it can distribute and cause side effects elsewhere in the body.”

“But if you think about it, you could use this sort of approach for any tumour or any disease that is confined to an organ, and you want to absorb the drug on the venous side before it can distribute and cause side effects elsewhere in the body.”

Early tests in pigs showed that the sponge soaked up on an average of 64% of a chemotherapy drug for liver cancer called doxorubicin, which was injected upstream.

The team is currently performing tests on the amount of drug that the sponge could absorb when implemented at the exit of a healthy pig liver.

They intend to obtain conditional approval from the US Food and Drug Administration (FDA) to investigate the drug sponge in humans.

Furthermore, the researchers hope that the sponge can potentially absorb other toxic drugs such as high-powered antibiotics.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology